Literature DB >> 18082555

Glycine transport inhibitors and the treatment of schizophrenia.

Daniel C Javitt1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18082555     DOI： 10.1016/j.biopsych.2007.09.017

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  28 in total

Review 1.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 2.  N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?

Authors:  Joshua T Kantrowitz; Daniel C Javitt
Journal:  Brain Res Bull       Date:  2010-04-24       Impact factor: 4.077

3.  Modulation of sensorimotor gating in prepulse inhibition by conditional brain glycine transporter 1 deletion in mice.

Authors:  Philipp Singer; Detlev Boison; Hanns Möhler; Joram Feldon; Benjamin K Yee
Journal:  Eur Neuropsychopharmacol       Date:  2010-07-19       Impact factor: 4.600

Review 4.  Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.

Authors:  Robert E McCullumsmith; John Hammond; Adam Funk; James H Meador-Woodruff
Journal:  Curr Pharm Biotechnol       Date:  2012-06       Impact factor: 2.837

5.  Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine.

Authors:  Segev Barak; Ina Weiner
Journal:  Psychopharmacology (Berl)       Date:  2010-02-24       Impact factor: 4.530

Review 6.  Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy.

Authors:  Detlev Boison; Philipp Singer; Hai-Ying Shen; Joram Feldon; Benjamin K Yee
Journal:  Neuropharmacology       Date:  2011-02-17       Impact factor: 5.250

Review 7.  Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential.

Authors:  Laetitia Mony; James N C Kew; Martin J Gunthorpe; Pierre Paoletti
Journal:  Br J Pharmacol       Date:  2009-07-08       Impact factor: 8.739

8.  Brain-specific disruption of the eIF2α kinase PERK decreases ATF4 expression and impairs behavioral flexibility.

Authors:  Mimi A Trinh; Hanoch Kaphzan; Ronald C Wek; Philippe Pierre; Douglas R Cavener; Eric Klann
Journal:  Cell Rep       Date:  2012-05-24       Impact factor: 9.423

9.  D-amino acid oxidase activity and expression are increased in schizophrenia.

Authors:  P W J Burnet; S L Eastwood; G C Bristow; B R Godlewska; P Sikka; M Walker; P J Harrison
Journal:  Mol Psychiatry       Date:  2008-07       Impact factor: 15.992

Review 10.  Modeling synaptogenesis in schizophrenia and autism using human iPSC derived neurons.

Authors:  Christa W Habela; Hongjun Song; Guo-Li Ming
Journal:  Mol Cell Neurosci       Date:  2015-12-02       Impact factor: 4.314
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.